drugset

drugset / Trial / NCT03035591

ODM-207 in Patients With Advance Solid Tumours

NCT03035591 ↗

Phase 1/2 Completed 36 enrolled Orion Corporation, Orion Pharma

NaSingle-groupOpen-labelBasic science

Summary

This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.

Timeline

Start: 2016-12-22
Primary completion: 2019-05-10
Completion: 2019-05-10

Publications

Ameratunga M, Brana I, Bono P, Postel-Vinay S, Plummer R, Aspegren J, Korjamo T, Snapir A, de Bono JS. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736. doi: 10.1038/s41416-020-01077-z. Epub 2020 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ODM-207	Small molecule	2 mg/kg	Oral

Indications